Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

This study tests a combination of TACE (transarterial chemoembolization — a procedure that delivers chemotherapy directly into the blood vessels feeding liver tumors and then blocks those vessels) plus bevacizumab (a drug that cuts off blood supply to tumors) in patients with liver metastases (cancer that has spread to the liver from another organ). **You may be eligible if...** - You have been diagnosed with cancer that has spread to the liver (liver metastases) - Your liver tumors are not suitable for surgery - Your liver is functioning reasonably well (Child-Pugh A or B) - The cancer outside your liver is stable - Liver tumors make up less than 70% of your liver volume - You are in good general health (ECOG 0–1) - Your life expectancy is more than 6 months **You may NOT be eligible if...** - You have an active infection - You have had prior liver surgery or previous TACE at another facility - You have serious liver complications like hepatic encephalopathy (liver-related brain problems), uncontrolled fluid in the abdomen, or esophageal variceal bleeding Talk to your doctor to see if this trial is right for you.